ArticleFrontiers in oncology2026

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

S Pelliccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.